Eli Lilly and Company
Senior Research Scientist- Protein Engineering
Targeted Molecules Corporation 2004 - 2005
Lead Scientist - Therapeutic Antibody Development
Biomedica 2001 - 2004
Research Scientist Iii - Vector Systems
Leucadia Technologies 2000 - 2001
Senior Research Scientist - Research and Development
Chiron/Corporation Viagene 1994 - 2000
Research Scientist - Vector Technologies
Education:
Colorado State University 1981 - 1985
Bachelors, Bachelor of Science, Microbiology
Skills:
Antibodies Biotechnology Drug Discovery Biopharmaceuticals Protein Chemistry Drug Development Elisa Technology Transfer Cell Culture Protein Purification Lifesciences Validation Gmp Protein Engineering Structural Biology
Interests:
Football Exercise Sweepstakes Home Improvement Shooting Donor Gourmet Cooking Sports Reading Golf Food Fishing Home Decoration Health Watching Sports Cooking Electronics Outdoors Sewing Baseball Crafts Fitness Games Music Dogs Movies Collecting Medicine Diet Automobiles Cats Travel Career Boating Watching Baseball Investing Traveling Watching Football
Dr. Driver graduated from the Univ of Sint Eustatius, Sint Eustatius, Netherland Antilles in 2008. He works in Bethesda, MD and specializes in Child & Adolescent Psychiatry and Psychiatry.
John M. Polo - San Diego CA David A. Driver - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C12N 516
US Classification:
435 691, 435455, 536 2372, 536 232, 536 241
Abstract:
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
John M. Polo - San Diego CA Carlos E. Ibanez - San Diego CA David A. Driver - San Diego CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
C12N 1563
US Classification:
4353201
Abstract:
Disclosed are recombinant alphavirus particles comprising a) an alphavirus vector construct which directs the expression of a heterologous nucleic acid molecule; b) a capsid protein; and c) an envelope glycoprotein from a virus different from said alphavirus vector.
John M. Polo - San Diego CA, US Carlos E. Ibanez - San Diego CA, US Stephen M. W. Chang - San Diego CA, US Douglas J. Jolly - Leucadia CA, US David A. Driver - San Diego CA, US Barbara A. Belli - San Diego CA, US
Assignee:
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:
C12N 15/63 C12N 15/85 A61K 48/00 C07H 21/04
US Classification:
4353201, 435325, 514 44
Abstract:
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
Compositions And Methods For Generating An Immune Response Utilizing Alphavirus-Based Vector Systems
John Polo - Hayward CA, US Ilya Frolov - St. Louis MO, US Jason P. Gardner - Pittsburg CA, US Gillis Otten - Foster City CA, US Susan Barnett - San Francisco CA, US David A. Driver - Solana Beach CA, US
Assignee:
Novartis Vaccines & Diagnostics, Inc. - Emeryville CA
International Classification:
C12N 7/08 A61K 35/76
US Classification:
4352351, 4242051, 424 931, 4353201
Abstract:
Methods are provided for generating immune responses utilizing alphavirus-based vector systems.
John M Polo - San Diego CA, US Carlos E Ibanez - San Diego CA, US Stephen M. W. Chang - San Diego CA, US Douglas J Jolly - Leucadia CA, US David A Driver - San Diego CA, US Barbara A Belli - San Diego CA, US
Assignee:
Novartis Vaccines & Diagnostics, Inc. - Emeryville CA
International Classification:
C12N 15/63 C12Q 1/68
US Classification:
4353201, 435 6
Abstract:
The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
David Albert Driver - Solana Beach CA, US Ryan James Darling - Fishers IN, US Maigorzata Donata Gonciarz - Indianapolis IN, US Radmila Micanovic - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 38/18
US Classification:
514 91
Abstract:
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
Compositions And Methods For Generating An Immune Response Utilizing Alphavirus-Based Vector Systems
John M Polo - Hayward CA, US Ilya Frolov - St. Louis MO, US Jason P Gardner - Pettsburg CA, US Gillis Otten - Foster City CA, US Susan Barnett - San Francisco CA, US David A Driver - Solana Beach CA, US
Assignee:
Novartis AG - Basel
International Classification:
C12N 15/79 C12N 15/01 C12N 15/09 A61K 48/00
US Classification:
4353201, 424 9321
Abstract:
Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and replicon particles for introducing heterologous sequences into cells for generating immune responses.
Thomas Dubensky - Rancho Sante Fe CA, US John Polo - San Diego CA, US Carlos Ibanez - San Diego CA, US Stephen Chang - San Diego CA, US Douglas Jolly - Leucadia CA, US David Driver - San Diego CA, US Barbara Belli - San Diego CA, US
Assignee:
Chiron Corporation
International Classification:
C12N015/861 C12N015/86
US Classification:
435/456000, 435/320100, 435/325000
Abstract:
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
Berlin, Conn.Project Manager - System Recruitment at Northeast... Past: Vice President - Business Development at Connecticut Economic Resource Center, President...